The information contained herein (the "Materials") is provided for informational and discussion purposes only and contains statements of opinion and belief. The Materials are not, and may not be relied on in any manner as, legal, tax, or investment advice. The Materials do not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor do they constitute an offer to provide investment advisory or other services by RA Capital Management, LLC and its affiliates and/or any investment products it advises (collectively, "RA Capital" or the "Firm"). Each recipient should make its own investigations and evaluations of RA Capital, and any investment products it advises, and should consult its own attorney, business adviser, and tax adviser as to legal, business, tax, and related matters thereto. The information contained in the Materials is not intended to be, and should not be viewed as, "investment advice" within the meaning of 29 C.F.R. §2510.3-21 or otherwise.

Any views expressed herein, unless otherwise indicated, are those of RA Capital as of the date indicated, are based on information available to RA Capital as of such date, and are subject to change, without notice, based on market and other conditions. No representation is made or assurance given that such views are correct and such views may have become unreliable for various reasons, including changes in market conditions or economic circumstances. Such views may have been formed based upon information, believed to be reliable, that was available at the time the Materials were published. Certain information contained herein concerning economic trends and/or data may be based on or derived from information provided by independent third-party sources. RA Capital believes that the sources from which such information has been obtained are reliable; however, it cannot guarantee the accuracy of such information and has not independently verified the accuracy or completeness of such information or the assumptions on which such information is based. RA Capital has no duty or obligation to update the information contained herein.

The content of the Materials neither constitutes investment advice nor offers any opinion with respect to the suitability of any security. Any references, either general or specific, to securities and/or issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, advice or recommendations to purchase, continue to hold, or sell such securities, or as an endorsement of any security or company. Certain current and prior investments may be highlighted in order to provide additional information regarding RA Capital’s investment strategy, the types of investments it pursues, and current or anticipated exit strategies. In addition, due to confidentiality restrictions, the information contained herein might not reference investments in certain companies. Accounts managed by RA Capital may invest in certain companies referenced in the Materials; however, RA Capital makes no guarantees as to accuracy or completeness of views expressed in the Materials. Any strategies and companies referenced in the Materials may not be suitable for all investors.

As stated above, the Materials are not an offer or solicitation for the purchase or sale of any security, including any interest in RA Capital Healthcare Fund, L.P. (the “Master Fund”) or RA Capital Healthcare International Fund Ltd. (the “Offshore Fund”), and, collectively with the Master Fund, the “Fund”), and should not be construed as such. Such an offer will only be made by means of a confidential Private Placement Memorandum (the “PPM”) to be furnished to qualified investors upon request. The information contained herein is qualified in its entirety by reference to the PPM, which contains additional information about the investment objective, terms, and conditions of an investment in the Fund, and also contains certain disclosures that are important to consider when making an investment decision regarding the Fund. In the case of any inconsistency between any information contained herein or in the Materials and the PPM, the terms of the PPM shall control.

The Materials are proprietary and confidential and may include commercially sensitive information. As such, the Materials must be kept strictly confidential and may not be copied or used for an improper purpose, reproduced, republished, or posted in whole or in part, in any form, without the prior written consent of RA Capital. The recipient of the Materials must not make any communication regarding the information contained herein, including disclosing that the Materials have been provided to such recipient, to any person other than its authorized representatives assisting in considering the information contained herein. Each recipient agrees to the foregoing and to return (or destroy upon RA Capital’s instructions) the Materials promptly upon request.

Any investment strategies discussed herein are speculative and involve a high degree of risk, including loss of capital. Investments in any products described herein and the Fund’s performance can be volatile, and investors should have the financial ability and be willing to accept such risks. An investor could lose all or a substantial amount of his or her investment. The Fund may be leveraged. Interests in the Fund are illiquid, as there is no secondary market for the Fund interests, and none is expected to develop. The Fund interests are subject to restrictions on transfer. Prior to investing in the Fund, investors should read the PPM and pay particular attention to the risk factors contained therein. Fees and expenses charged in connection with an investment in the Fund may be higher than the fees and expenses of other investment alternatives and may offset investment profits of the Fund. RA Capital has total trading authority over the Fund. The use of a single advisor applying generally similar trading programs could mean lack of diversification and, consequentially, higher risk. A portion of the trades executed for the Fund may take place on foreign exchanges. It should not be assumed, and no representation is made, that past investment performance is reflective of future results. Nothing herein should be deemed to be a prediction or projection of future performance. To the extent any prior or existing investments are described, RA Capital makes no representations, and it should not be assumed, that past investment selection is necessarily reflective of future investment selection, that any performance discussed herein will be achieved or that similar investment opportunities will be available in the future or, if made, will achieve similar results.

In particular, to the extent valuation information is provided for any unrealized investments, such valuations are RA Capital’s estimates as of the date set forth in the Materials, and there can be no assurance that unrealized investments will be realized at such valuations. While RA Capital believes any valuations presented herein are reasonable, such valuations may be highly subjective, particularly for private investments, and are based on information provided by third parties and/or RA Capital’s assumptions, any or all of which might be mistaken or incomplete. Actual realized returns will depend on, among other factors, future operating results, the value of the assets and market conditions at the time of disposition, any related transaction costs, and the timing and manner or sale, all of which may differ from the assumptions on which the valuations contained herein are based. As a result of the foregoing, actual realized returns may differ materially from the valuations contained herein.

Certain information contained in this document constitutes “forward-looking statements,” which can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “target,” “project,” “estimate,” “intend,” “continue,” or “believe,” or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, actual events or results or the actual performance of any investment may differ from those reflected or contemplated in such forward-looking statements. Prospective investors should not rely on these forward-looking statements when making an investment decision.

None of the information contained herein has been filed with the U.S. Securities and Exchange Commission, any securities administrator under any securities laws of any U.S. or non-U.S. jurisdiction, or any other U.S. or non-U.S. governmental or self-regulatory authority. No such governmental or self-regulatory authority will pass on the merits of any offering of interests by RA Capital or the adequacy of the information contained herein. Any representation to the contrary is unlawful. The interests in the Fund are not registered under the U.S. Securities Act of 1933 as amended, or qualified or registered under any applicable state, local, provincial, or other statutes, rules, or regulations. The Fund has not been, and will not be, registered as an investment company under the U.S. Investment Company Act of 1940, as amended.
INVESTING UPSTREAM

BY STEVE EDELSON, SENIOR EDITOR

After a decade of focusing on public investments and later adding private investments to its remit, RA Capital is getting into the business of starting companies from whole cloth. The firm thinks having a dedicated financier from start to acquisition or profitability offers the continuity of support that many companies are seeking.

RA Capital isn’t revealing many details about its initial two newcos, except to say the areas will include dermatology and Orphan diseases. Nevertheless the move will put the firm in a rare position of being a single institution that participates in the entire financing spectrum from formation to investing in well-established public companies.

“You have a single cohesive team pulling in a single direction, with maximal flexibility to invest in wherever the science and the value take us,” said the firm’s Peter Kolchinsky. “Science doesn’t care about whether you’re public or private, LLC or C-Corp.”

One constant that will remain regardless of stage is RA Capital’s desire to infuse enough money into companies so they can pursue multiple programs in parallel. The goal is to own biotechs that do not live or die based on one binary event.

UNCONVENTIONAL UPBRINGING

RA Capital is named after Richard Aldrich, a co-founder of Vertex Pharmaceuticals Inc., and began life in 2001 when he hired Kolchinsky to manage about $4 million.

Kolchinsky’s first job was triaging the portfolio. “We discovered the discipline of not looking backwards at cost basis, but asking the question ‘if we didn’t have the stock today, would we be buying it?’ he said. “If the answer was ‘no,’ we sold it.”

The firm’s early wins included an investment in HIV company Triangle Pharmaceuticals Inc., which Gilead Sciences Inc. acquired for $464 million in cash in early 2003.

Rajeev Shah joined RA Capital in 2004 and he and Kolchinsky increased the pace of analyzing companies and set about challenging the conventional wisdoms about investing.

For example, Kolchinsky and Shah challenged the notion that the stock of companies short on cash suffered from a financing overhang. “If everybody is afraid of the overhang, there’s going to be a buildup of demand and you might be better off buying the stock on the open market instead of waiting to buy it in an offering,” said Shah. “The notion of an overhang didn’t apply to good companies. That was evident in the data, but it was conventional wisdom that caused people to miss out.”

“The science being done today throughout the industry merits more capital.”

PETER KOLCHINSKY, RA CAPITAL

Shah added, “Sometimes we stepped up when no one else would, so we basically built a position and made the financing overhang go away at the same time.”

PRIVATE LIFE

RA Capital made one of its first private investments in 2010 when it participated in a $15 million series C round for diagnostic company T2 Biosystems Inc.

“T2 was compelling because our diligence on antibiotics kept telling us that physicians could do a lot more with the drugs they already had if only they could know sooner which bugs were making a patient sick, within hours instead of days. T2 had evidence they could crack this problem, so we wanted to be on the right side of what seemed like a likely disruptive innovation,” said Kolchinsky.
T2 markets its T2Candida Panel to detect sepsis-causing Candida.

For the next two years, T2 was one of only a few recipients of RA’s private dollars.

Things changed in 2012 when RA began to explore the private markets in earnest. The private push coincided with two events, one internal and the other external.

Outside the firm, the markets were heating up and biotech was leading the pack. The reemergence of a biotech IPO window meant there was an arbitrage opportunity. Firms able to participate in a biotech’s mezzanine round could be promptly rewarded with a step-up in valuation when the company went public.

Internally, RA had formed its TechAtlas research division, which now consists of about 40 employees dedicated to making detailed maps of a given therapeutic area.

The maps look at standard of care, and then delve into all industry pipeline programs for the disease, analyzing competitive strengths and weaknesses and the potential for combinations (see “TechAtlas Drugged”).

From those maps, RA looks for companies with the best solution set for a disease or therapeutic area.

In some cases, the maps showed that a private company’s asset trumped what was available among public companies.

For example, Kolchinsky said, RA’s research on Pain Therapeutics Inc. led the firm to Collegium Pharmaceutical Inc. In 2015, RA participated in Collegium’s $50 million series D round. Both companies are developing abuse-deterrent compounds for pain.

The firm now is one of the most active crossover investors in biotech. Since the start of 2012, RA Capital has invested in private financings for at least 45 biotech companies. Of those, 23 are now public.

“We focus on making sure our companies are well capitalized,” said Kolchinsky. “A great team, especially a well-resourced team, can do great science and come up with lots of options and the companies stop being so binary. The science being done today throughout the industry merits more capital.”

Beginning in 2012, the median sizes of series A, B and C rounds in which RA Capital participated were $23.3 million, $46.5 million and $52.5

---

**TECHATLAS DRUGGED**

RA Capital’s TechAtlas research division analyzes and maps broad swaths of biology to help drive its investment decisions. Below is an excerpt from the firm’s B cell malignancy map, which informed RA Capital’s investment in TG Therapeutics Inc. (NASDAQ:TGTX). Although no single TG asset is the most advanced in a given category, the firm views TG as the most solution-oriented, rather than asset-oriented, biotech focused on B cell malignancies. Source: RA Capital

<table>
<thead>
<tr>
<th>Legend</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>NDA</th>
<th>NDA filed</th>
<th>Markedeted</th>
</tr>
</thead>
<tbody>
<tr>
<td>O</td>
<td>Preclinical</td>
<td>Phase I</td>
<td>Phase II</td>
<td>Phase III</td>
<td>NDA</td>
<td>NDA filed</td>
<td>Markedeted</td>
</tr>
<tr>
<td>++</td>
<td>Beigene</td>
<td>Incyte</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>++</td>
<td>Principia</td>
<td>Rhizen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>++</td>
<td>Sunesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Solution Developers**

<table>
<thead>
<tr>
<th>Solution Developers</th>
<th>Must-Haves</th>
<th>Add-ons/Follow-ons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche</td>
<td>M Rituxan, M Gazyva</td>
<td>BTK, PI3K-δ, Sorivac</td>
</tr>
<tr>
<td>JNJ</td>
<td>M Imbruvica (w/ AbbVie, Ono)</td>
<td>Duetib (w/ Infinity), BTK, PI3K-δ, Medivation (NDA until, formerly anti-PD1)</td>
</tr>
<tr>
<td>Gilead</td>
<td>GS-4059 (w/ Ono)</td>
<td>Zydelig, Duetib (w/ Infinity), BTK, PI3K-δ, Medivation (NDA until, formerly anti-PD1)</td>
</tr>
<tr>
<td>AbbVie</td>
<td>M Imbruvica (w/ JNJ)</td>
<td>M Zydelig, Duetib (w/ Infinity), BTK, PI3K-δ, Medivation (NDA until, formerly anti-PD1)</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>Acalabrutinib (w/ Acerta)</td>
<td>ACP-319 (w/ Acerta)</td>
</tr>
<tr>
<td>Novartis</td>
<td>M Aziara</td>
<td>NDA (for CLL) Venetoclax (w/ AbbVie)</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>M Arzerra</td>
<td>NDA (for CLL) Venetoclax (w/ Roche)</td>
</tr>
</tbody>
</table>

**Must-Haves**

- Anti-CD20 mAbs
- B cell receptor pathway inhibitors
  - BTK
  - PI3K-δ

**Add-ons/Follow-ons**

- BCL-2 inhibitor
- Oral EZH2 inhibitor
- Checkpoint inhibitors/agonists
  - Anti-PD-L1, anti-GITR (w/ Checkpoint/ Fortress)
The firm also invested last year in the series A round of Taris Biomedical LLC, which was formed in 2013 when the stock was trading around $30 per share, or $30 million financing for Dyax at a share price of $202-462-9582; Fax: +1 202-667-2922

All information provided through BioCentury Publications, Inc.’s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see “Use of Images” found under the “About Us” tab on the Homepage at www.biocentury.com.

All contents Copyright © 2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Publications, Inc. No part of BioCentury or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury Publications, Inc., which may be requested from Reprints/Permissions at www.biocentury.com.

**Trademarks:** BioCentury; BCI®; The BioCentury 100®; Because Real Intelligence is Hard to Find®; and The Clear Route to ROI® are trademarks of BioCentury Publications, Inc.

In almost all cases, RA Capital expects the endgame will be acquisitions by big biotech and pharma.

“It’s plausible that one of these large giants will simply say, ‘I need growth more than you and I’m willing to pay the price,’” said Kolchinsky.

The firm’s most recent M&A exit was Dyax Corp., a developer of therapies for hereditary angioedema (HAE). This year, Shire plc completed the acquisition for $37.50 per share, or $5.9 billion in cash.

RA first invested in Dyax in 2011 when the stock was trading around $1. In 2013, RA led a $30 million financing for Dyax at a share price of $2.30.

**COMPANIES AND INSTITUTIONS MENTIONED**

Collegium Pharmaceutical Inc. (NASDAQ:COLL), Canton, Mass.
Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif.
Pain Therapeutics Inc. (NASDAQ:PTIE), Austin, Texas
Qvella Corp., Richmond Hill, Ontario
RA Capital Management LLC, Boston, Mass.
Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland
Taris Biomedical LLC, Lexington, Mass.
TA Biosystems Inc. (NASDAQ:TTOO), Lexington, Mass.
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass.
Wave Life Sciences Ltd. (NASDAQ:WVE), Cambridge, Mass.

**REFERENCES**